Efruxifermin

依鲁西夫明

Report date: 2025/02/08 10:33:14

Base Information

Drug NameEfruxifermin
Drug Alias NameAKR-001AMG-876EFXFc-FGF21(RGE)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionFibroblast growth factor 21 agonistsFibroblast Growth Factor Receptor 1c agonistsFibroblast Growth Factor Receptor 2c agonists +[4] 
TargetsFibroblast growth factor 21Fibroblast Growth Factor Receptor 1cFibroblast Growth Factor Receptor 2c +[4] 
Therapy Area/IndicationsDiabetes MellitusLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[19] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAkero Therapeutics Inc
Inactive CompaniesAmgen Inc
Active IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG